{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Interleukin-6 Inhibitors: Improving Biologic Specificity in the Control of Rheumatoid Arthritis - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"NfH1vlJ0vx\"><a href=\"https:\/\/themedicalxchange.com\/en\/2015\/06\/23\/european-league-against-rheumatism-eular-2015-cong\/\">Interleukin-6 Inhibitors: Improving Biologic Specificity in the Control of Rheumatoid Arthritis<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2015\/06\/23\/european-league-against-rheumatism-eular-2015-cong\/embed\/#?secret=NfH1vlJ0vx\" width=\"600\" height=\"338\" title=\"&#8220;Interleukin-6 Inhibitors: Improving Biologic Specificity in the Control of Rheumatoid Arthritis&#8221; &#8212; The Medical Xchange\" data-secret=\"NfH1vlJ0vx\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2015\/06\/2354_EULAR_2015_Table_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Rome \u2013 A new wave of biologics targeted at interleukin-6 (IL-6) is expected to provide an incremental advance in the treatment of rheumatoid arthritis (RA), judging from data presented at this year\u2019s EULAR. Relative to tumor necrosis factor alpha (TNF-\u03b1), IL-6 may be a more rational biologic target because of evidence that it is active earlier in the course of RA pathophysiology, may be more directly implicated in pain signaling, and can be linked closely to major molecular processes driving joint destruction. Several new generation IL-6 inhibitors have reached late stages of clinical testing with promising activity and acceptable tolerability. The newer agents have the potential to build upon the efficacy of earlier generations of biologics."}